Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?

Peer Review reports

Original Submission
18 Sep 2019	Submitted	Original manuscript
30 Oct 2019	Reviewed	Reviewer Report - Michael Power
8 Nov 2019	Reviewed	Reviewer Report - Romana Pylypchuk
17 Jan 2020	Author responded	Author comments - Gijs F.N. Berkelmans
26 Jan 2020	Reviewed	Reviewer Report - Michael Power
11 Mar 2020	Author responded	Author comments - Gijs F.N. Berkelmans
Resubmission - Version 2
17 Jan 2020	Submitted	Manuscript version 2
Publishing
13 Mar 2020	Editorially accepted
16 Apr 2020	Article published	10.1186/s41512-020-00072-5

Back to article page